Cost cuts are coming for Allergan, CEO Brent Saunders says

Discussion in 'Allergan' started by anonymous, Nov 3, 2017 at 5:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    While I understand this has become almost solely a sales board you all are overly focused on the implications the announced cost cutting will have on the US sales force. Allergan is a huge company with world wide capacities. While I can't suggest the US sales force won't be affected to some degree by these upcoming actions, I do suggest the "blood bath" so many fear will not occur. This division was already right-sized earlier in 2017. There may well be additional cuts, but they won't be nearly as drastic as some here may be led to believe. Around the globe there will be massive restructuring and reduction, but that will focus on big ticket research, development, manufacturing and administrative positions as well as capitol items such as facilities. In my country alone we know of 2 facilities facing closure. So, you in the US will see results from these cuts, but realize this company is much more than just you.
     
  2. anonymous

    anonymous Guest

     
  3. anonymous

    anonymous Guest

    Do the math for the layoffs. Respect for the way this company handles business is gone. Employees want to be laid off due to the fact that leadership is a laughable group who care only for themselves. It is a sad time for pharma. Over the last 30 years business has become disrespected.
     
  4. anonymous

    anonymous Guest

    We just had a restructuring of the sales force. So there can’t be much more cut there unless the company lets go of a couple of PC drugs which they could do I suppose..Namzaric & Viberzi. They could easily reduce or eliminate most of the Specialty Rep positions. They call on the same people as PC & SR are so much more costly financially to the company.
    They really need to restructure the DMs. I mean like cut them in half. 1 DM could cover 16-20 reps easily. With technology so much can be fine electronically. Field Rides every 4-6 weeks is over kill anyway. You can tell by riding with a rep for 2 days whether they’re doing their job or not. So a ride along once every 3 months is sufficient. Plus more and more offices don’t allow us as DMs to access them with reps anyway.
    Cost cuts will come from reduced spending on commercials, meetings, samples, facilities, etc.
     
  5. anonymous

    anonymous Guest

    I wouldn't take anything off the table as far as cuts go. Facility closures may be on the table as well. I certainly hope that there are no further cuts to R&D. Allergan needs R&D in order to continue to grow. Total S, G & A spend is much higher than R&D spend. When I looked at the financial statements, I was really surprised at how high S, G & A was.
     
  6. anonymous

    anonymous Guest

    What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The
    Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will.
     
  7. anonymous

    anonymous Guest

    Are neurotransmitter sales performing well???
     
  8. anonymous

    anonymous Guest

    "What is the most valuable franchise? Restasis. BS has built and nurtured it during his tenure and this should not be expected to change. We will double down to fight Imprimis. The
    Intranasal Tear Neurostimultor is a winner in the dry eye space as well. Restasis has the brand name that commands a premium and always will."

    Imprimis is not the biggest threat to Restasis by a long shot. Imprimis is a small compound pharmacy. They are trying to ride the coat tails of Restasis news but they can't make Restasis. They can compound Cyclosporine eye drops that aren't commercially available and only then if a doctor specifically requests for a patient based on a medical need (allergic to an ingredient or something). I don't know about you but I have never in my lifetime for me or any family member had a doctor prescribe a drug that required compounding. The market share for compound drugs is small.

    The biggest threat to Restasis is the loss of the patent exclusivity and the entry of other dry eye medications. I agree that Allergan will continue to try and protect the Restasis franchise.
     
  9. anonymous

    anonymous Guest

    Haven’t heard about a neurotransmitter. My friend is Botox neuro and he doesn’t sell it.
     
  10. anonymous

    anonymous Guest

    Viberzi is very important to the company n they will not drop it. it has been doing good n promising
     
  11. anonymous

    anonymous Guest

    BS has no emotional attachment to Viberzi like he does with Restasis. You can take that to the bank. He may not know what it does. Lomotil has patient more value than Viberzi. He built Restasis to where it is today.
     
  12. anonymous

    anonymous Guest




    Legacy Allergan built and nurtured Restasis and nobody else. Saunders had a billion dollar gift thrown in his lap. Make no mistake!
     
  13. anonymous

    anonymous Guest

    Completely agree with this poster. Restasis was on track to be a billion dollar drug before the Actavis buyout occurred. Of course Brett loves it. Every CEO loves their blockbuster products.

    Legacy Allergan invested a lot of research into understanding dry eye. Restasis was very difficult to get approved.
     
  14. anonymous

    anonymous Guest

    I agree the legacy Allergan put in the resources to learn how to dominate the dry eye space but we would have been a better company under BS than DP.
     
  15. anonymous

    anonymous Guest



    I think you mean Pyott over Saunders! Indeed! Pyott makes Saunders look like a school boy!